Business Description
Eurobio Scientific
SIC : 2835
ISIN : FR0013240934
Share Class Description:
STU:E8TN: Bearer and/or Registered shares issued from reverse splitTotal Employee Number:
343Compare
Compare
Traded in other countries / regions
ALERS.FranceE8TN.Germany IPO Date
2020-05-12Description
Eurobio Scientific SA is a French in vitro diagnostics company that develops, manufactures, and distributes specialty diagnostic products and life-science research tools. Its diagnostics portfolio covers infectious disease serology, transplantation monitoring, autoimmune and allergy testing, and molecular biology, including rapid tests and multiplex assays. The company also supplies reagents, antibodies, and instrumentation to hospital laboratories, private clinical labs, and research institutions. It operates mainly in France and other European markets, with additional sales through distributors internationally. Revenue comes from selling diagnostic kits and reagents, life-science products, and related services, supplemented by distribution agreements for third-party instruments and assays. Eurobio Scientific has grown partly through acquisitions, expanding its test menu and geographic reach, and serves both routine clinical testing and specialized research applications.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.29 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.6 | |||||
Interest Coverage | 5.55 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.68 | |||||
Beneish M-Score | -2.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7 | |||||
3-Year EBITDA Growth Rate | -9.7 | |||||
3-Year EPS without NRI Growth Rate | -40.2 | |||||
3-Year FCF Growth Rate | -44.2 | |||||
3-Year Book Growth Rate | 2.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 94.98 | |||||
9-Day RSI | 88.72 | |||||
14-Day RSI | 82.19 | |||||
3-1 Month Momentum % | -7.21 | |||||
6-1 Month Momentum % | -5.72 | |||||
12-1 Month Momentum % | -17.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.98 | |||||
Quick Ratio | 1.36 | |||||
Cash Ratio | 0.45 | |||||
Days Inventory | 113 | |||||
Days Sales Outstanding | 72.71 | |||||
Days Payable | 64.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.5 | |||||
Shareholder Yield % | 17.2 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 45.58 | |||||
Operating Margin % | 6.37 | |||||
Net Margin % | 2.89 | |||||
EBITDA Margin % | 15.83 | |||||
FCF Margin % | 2.71 | |||||
OCF Margin % | 10.16 | |||||
ROE % | 2.68 | |||||
ROA % | 1.89 | |||||
ROIC % | 3.18 | |||||
3-Year ROIIC % | 108.31 | |||||
ROC (Joel Greenblatt) % | 24.5 | |||||
ROCE % | 4.55 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 55.86 | |||||
Forward PE Ratio | 18.14 | |||||
PE Ratio without NRI | 54.69 | |||||
Shiller PE Ratio | 14.86 | |||||
Price-to-Owner-Earnings | 16.86 | |||||
PS Ratio | 1.59 | |||||
PB Ratio | 1.42 | |||||
Price-to-Tangible-Book | 8.15 | |||||
Price-to-Free-Cash-Flow | 42.7 | |||||
Price-to-Operating-Cash-Flow | 14.39 | |||||
EV-to-EBIT | 25.56 | |||||
EV-to-EBITDA | 9.35 | |||||
EV-to-Forward-EBITDA | 5.28 | |||||
EV-to-Revenue | 1.48 | |||||
EV-to-Forward-Revenue | 1.52 | |||||
EV-to-FCF | 31.79 | |||||
Price-to-GF-Value | 0.97 | |||||
Price-to-Projected-FCF | 0.54 | |||||
Price-to-Median-PS-Value | 1.43 | |||||
Price-to-Graham-Number | 4.45 | |||||
| Price-to-Net-Current-Asset-Value | 14.11 | |||||
Earnings Yield (Greenblatt) % | 3.91 | |||||
FCF Yield % | 2.47 | |||||
Forward Rate of Return (Yacktman) % | -7.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eurobio Scientific Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 168.595 | ||
| EPS (TTM) (€) | 0.483 | ||
| Beta | 0.7556 | ||
| 3-Year Sharpe Ratio | 0.29 | ||
| 3-Year Sortino Ratio | 0.69 | ||
| Volatility % | 20.26 | ||
| 14-Day RSI | 82.19 | ||
| 14-Day ATR (€) | 0.925904 | ||
| 20-Day SMA (€) | 20.31 | ||
| 12-1 Month Momentum % | -17.76 | ||
| 52-Week Range (€) | 18.8 - 25.45 | ||
| Shares Outstanding (Mil) | 10.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eurobio Scientific Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eurobio Scientific Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eurobio Scientific Frequently Asked Questions
What is Eurobio Scientific(STU:E8TN)'s stock price today?
The current price of STU:E8TN is €24.70. The 52 week high of STU:E8TN is €25.45 and 52 week low is €18.80.
When is next earnings date of Eurobio Scientific(STU:E8TN)?
The next earnings date of Eurobio Scientific(STU:E8TN) is .
Does Eurobio Scientific(STU:E8TN) pay dividends? If so, how much?
Eurobio Scientific(STU:E8TN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers